5 acquisitions that forced Big Pharmas to co-parent
Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” according to one biotech consultant.
comments(0)
5-min edit window · permanent after that